Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1701-1720 of 3,900 trials

Takotsubo Syndrome: Beta-Blockers Study

We are investigating whether beta-blockers can help improve heart function in patients with Takotsubo Syndrome. This study will also look at various heart health measures and quality of life.

Takotsubo Syndrome1-2 yearsMonitoring phase (IV)6-10 visitsPartially RemoteCardiologyInternal Medicine

Recurrent Glioblastoma: Personalized Drug Strategy

We are testing a personalized treatment approach for patients with recurrent glioblastoma to see if tailored drug combinations improve tumor response and overall survival. The study also looks at any side effects from the treatments.

Recurrent Glioblastoma1-2 yearsSafety phase (I)No PlaceboStandard MedicinesNeurologyOncology

GSDIa: DTX401 Treatment Study

We are examining the long-term safety and pregnancy outcomes of DTX401 for individuals with GSDIa. This study will help us understand how effective this treatment is over time.

Glycogen Storage Disease Type IA>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Bronchiectasis: Inhaled Antibiotics Study

We are studying whether inhaled antibiotics can help reduce bacterial infections in patients with bronchiectasis after initial treatment. This trial compares the effects of inhaled antibiotics to a placebo.

Adult Bronchiectasis1-2 yearsStandard MedicinesInternal MedicinePulmonology

Multiple Sclerosis: Stem Cell Treatment Study

We are investigating whether a new stem cell treatment can help regenerate nerve function in patients with progressive multiple sclerosis. The study will also assess safety and other health measures.

Multiple Sclerosis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

BCR/ABL1-Like Acute Lymphoblastic Leukemia: Ponatinib and Chemotherapy

We are studying a new treatment combining ponatinib and chemotherapy for adults with BCR/ABL1-like acute lymphoblastic leukemia. The aim is to improve remission rates and monitor disease response over time.

Acute Lymphoblastic LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Rare Cancers: Dendritic Cell Vaccine Study

We are testing a new vaccine made from patients' own tumor cells for those with resected stage IV neuroendocrine tumors and soft tissue sarcomas. The study aims to evaluate safety and how well the immune system responds to the treatment.

Soft Tissue SarcomaNeuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: FBL-MTX Injection Study

We are investigating a new injectable treatment for moderate-to-severe rheumatoid arthritis in patients who haven't used DMARDs or have had issues with oral methotrexate. The study will evaluate how well it works and its safety.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Behçet's Syndrome: Steroids Plus Anticoagulants Study

We are investigating whether adding anticoagulants to steroid therapy helps reduce the risk of deep venous thrombosis relapse in people with Behçet's syndrome. This study will also look at safety and quality of life.

Behcet's Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHematologyInternal MedicineRheumatology

Solid Tumors: E7386 with Other Anticancer Drugs

We are studying the safety and effectiveness of E7386 combined with other anticancer treatments for patients with solid tumors. This trial aims to find the best dose and assess how well it works compared to standard therapies.

Liver Cancer (Hepatocellular Carcinoma)Colorectal CancerEndometrial CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Oral Midazolam for Patients Refusing Care

We are studying whether oral midazolam can help older patients with moderate to severe cognitive disorders accept necessary care. The trial also looks at its safety and the satisfaction of healthcare providers.

Cognitive Issues and Agitation in the Elderly>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyPsychiatry

Niemann-Pick Disease Type C: N-Acetyl-L-Leucine Study

We are investigating whether N-Acetyl-L-Leucine can improve symptoms and quality of life for individuals with Niemann-Pick disease type C. The study also looks at the safety of this treatment for both older and younger patients.

Niemann-Pick Disease Type C3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyNeurology

Prurigo Nodularis: Barzolvolimab Study

We are testing a new medication, barzolvolimab, for people with prurigo nodularis to see if it helps reduce itching and improve skin lesions. The study will also look at the safety of this treatment and its effects on quality of life.

Prurigo Nodularis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Urinary Incontinence in Children: StayDry Study

We are exploring how stopping medication for urinary incontinence affects recurrence and overall well-being in children. The study compares abrupt versus gradual withdrawal of treatments like solifenacin and mirabegron.

Daytime Urinary Incontinence>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesUrology

Sickle Cell Disease: BMS-986470 Study

We are testing a new medication, BMS-986470, to see if it is safe and well-tolerated in healthy volunteers and people with sickle cell disease. The study aims to find the best dose and evaluate its effects on hemoglobin levels.

Sickle Cell DiseaseSafety phase (I)Efficacy phase (II)Investigational MedicinesHematologyInternal Medicine

Acute Myeloid Leukemia: Ziftomenib Combinations

We are investigating the safety and tolerability of Ziftomenib in patients with relapsed or refractory acute myeloid leukemia. This study aims to understand how well this treatment works alongside other therapies.

Relapsed Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment

We are studying whether axatilimab, combined with corticosteroids, helps improve symptoms in patients with moderate to severe chronic graft-versus-host disease. This trial compares its effects to a placebo.

Chronic Graft-Versus-Host DiseaseConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Chronic Inflammatory Diseases: Low-Dose Interleukin-2 Therapy

We are studying the safety and effectiveness of low-dose interleukin-2 therapy for patients with conditions like Pemphigus vulgaris and Mucous Membrane Pemphigoid. This trial aims to see how well this treatment works compared to a placebo.

Primary Sclerosing Cholangitis (PSC)Mucous Membrane PemphigoidPolymyositis/Dermatomyositis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious DiseasesRheumatology

Gene Therapy for Central Nervous System Cancer

We are exploring a new gene therapy using stem cells for patients with cancer in the central nervous system. This study aims to see if it can improve treatment outcomes for these patients.

GlioblastomaSafety phase (I)Efficacy phase (II)NeurologyOncology